PMID: 10767572Apr 18, 2000Paper

Salt form selection and characterization of LY333531 mesylate monohydrate

International Journal of Pharmaceutics
G L EngelL L Winneroski


LY333531 is a potent protein kinase C(beta) (PKC(beta)) inhibitor currently under development for the treatment of diabetic complications. Seven salts of LY333531 (hydrochloride, sulfate, mesylate, succinate, tartrate, acetate and phosphate) were evaluated during the early phase of development. Physical property screening techniques including microscopy, DSC, TGA, XRPD, hygroscopicity and solubility were utilized to narrow the selection to two salts: the mesylate and hydrochloride. Identification of the optimal salt form was based upon solubility, bioavailability, physical stability and purity. During the evaluation process three hydrated forms (anhydrate, monohydrate, and tetrahydrate) of the hydrochloride salt were identified. The mesylate salt was found to give only one, a monohydrate. Processing parameters (e.g. filtration rate, crystal form stability) demonstrated that the anhydrate was the preferred form of the hydrochloride salt. Bioavailability studies in dogs indicated that the C(max) and area under the plasma concentration vs. time curve (AUC) for LY333531 and its active metabolite, LY338522, following administration of the mesylate salt were approximately 2.6 times those obtained after the LY333531 HCl dose. This dif...Continue Reading


Jan 1, 1977·Journal of Pharmaceutical Sciences·S M BergeD C Monkhouse
Feb 1, 1988·British Journal of Clinical Pharmacology·A JamaludinK H Yuen
Jul 1, 1986·Biopharmaceutics & Drug Disposition·L M WalmsleyJ O Hunter
Jun 1, 1981·Journal of Pharmaceutical Sciences·S MiyazakiT Nadai

❮ Previous
Next ❯


Jan 10, 2009·The Journal of Antibiotics·Hirofumi Nakano, Satoshi Omura
Jul 18, 2002·Nature Reviews. Drug Discovery·Philip Cohen
Aug 15, 2003·AAPS PharmSciTech·Jaber G QasemGeorge A Digenis
Dec 20, 2012·AAPS PharmSciTech·Lokesh KumarArvind K Bansal
Jan 1, 2014·Journal of Computer-aided Molecular Design·Li XingElizabeth A Lunney
Aug 23, 2008·Pharmaceutical Development and Technology·Lokesh KumarArvind K Bansal
Dec 24, 2005·Pharmaceutical Development and Technology·Julie K SpenceSuresh R Babu
Mar 1, 2012·Drug Development and Industrial Pharmacy·Kalle SigfridssonYudong Wang
May 30, 2012·Drug Development and Industrial Pharmacy·A S SheteM S Murthy
Nov 26, 2009·Expert Opinion on Pharmacotherapy·Ronald P Danis, Matthew J Sheetz
Jun 29, 2011·Drug Development and Industrial Pharmacy·Kalle SigfridssonKristina Ohlson
Mar 29, 2013·Expert Opinion on Drug Delivery·Sonali S Bharate, Ram A Vishwakarma
Jan 31, 2015·Expert Opinion on Drug Metabolism & Toxicology·Candido G Da SilvaGodefridus J Peters
Nov 14, 2008·Drug Development and Industrial Pharmacy·Tu Lee, Yeh Wen Wang
Nov 4, 2004·Drug Development and Industrial Pharmacy·Beom Soo ShinSun Dong Yoo
Jan 4, 2012·Journal of Pharmaceutical Sciences·Kristyn Greco, Robin Bogner
Oct 25, 2011·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Pranav KarmwarThomas Rades
May 26, 2009·International Journal of Pharmaceutics·Hyungchul KimDiane J Burgess
Oct 9, 2007·International Journal of Pharmaceutics·Takashi KojimaTakashi Mano
Jul 10, 2007·Advanced Drug Delivery Reviews·Abu T M Serajuddin
Jan 25, 2008·Proteins·Sishi TangLakshmi P Kotra
Jan 26, 2006·British Journal of Clinical Pharmacology·Kwee Poo YeoStephen D Wise
Apr 27, 2011·Annals of Neurology·David KremerPatrick Küry
Mar 28, 2006·Regulatory Toxicology and Pharmacology : RTP·David J Snodin
Jan 18, 2006·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·R K VerbeeckR B Walker
Apr 22, 2014·International Journal of Pharmaceutics·Catarina FlorindoIsabel M Marrucho
Nov 3, 2016·Molecular Pharmaceutics·Naveen K ThakralGregory A Stephenson
Jul 18, 2002·Nature Reviews. Drug Discovery·Margaret A Somerville
Aug 19, 2007·American Journal of Hematology·Donald LavelleJoseph Desimone
Apr 1, 2006·Pharmaceutical Research·Takashi KojimaYoshihisa Matsuda
Apr 12, 2007·Physiological Genomics·Dan ChalothornJames E Faber
Feb 7, 2013·Pharmacological Reviews·Hywel D WilliamsChristopher J H Porter
Jun 5, 2014·Archives of Pharmacal Research·Roshan PradhanJong Oh Kim
Mar 2, 2018·Journal of Parasitic Diseases : Official Organ of the Indian Society for Parasitology·Samia E EtewaMahmoud A El-Shafey
Aug 9, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Barbara J RingSteven A Wrighton
Jan 24, 2021·International Journal of Pharmaceutics·Peter J Skrdla
Dec 7, 2007·Journal of Medicinal Chemistry·G Steffen PaulekuhnChristoph Saal
May 13, 2010·Molecular Pharmaceutics·Kristyn Greco, Robin Bogner

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
Hyo-Kyung Han, Hoo-Kyun Choi
Journal of Pharmaceutical Sciences
S M BergeD C Monkhouse
© 2021 Meta ULC. All rights reserved